Introduction
High-dose immunosuppressive therapy followed by autologous or allogeneic stem cell transplantation (SCT) might reduce autoimmune disease activity. For example, experiments using this approach in murine multiple sclerosis (MS) showed control of the disease after SCT. 1, 2 Earlier clinical studies indicated that long-term remissions of several autoimmune diseases could be achieved after SCT. [3] [4] [5] Here, we applied extensive ex vivo and in vivo T-cell depletion in combination with autologous SCT as salvage treatment for MS. Ex vivo T-cell depletion was done by preparing autografts enriched for CD34 þ hematopoietic stem cells, while in vivo T-cell depletion was accomplished by administration of antithymocyte globuline (ATG) and total body irradiation (TBI). 6 Although immune reconstitution has been extensively studied after unmodified and CD34-enriched autologous SCT, [7] [8] [9] [10] [11] [12] [13] [14] only recently data have become available on autologous SCT recipients pretreated with intensive ex vivo and in vivo T-cell depletion in the setting of autoimmune disease. 15, 16 Here, we compared the kinetics of T-cell recovery in MS patients treated with this approach with that in patients with hematological malignancies (HM) receiving unmodified autografts. We studied absolute T-cell subset counts, expression of T-cell activation markers, and simultaneous analyses of CD4 þ and CD8 þ T-cell function as measured by the induction of various cytokine responses after in vitro lymphocyte stimulation during the first year post SCT. As we anticipated that the T-cell recovery in the intensively T-depleted MS patient group would be delayed and could predispose these patients for infectious problems, we compared the occurrence of clinically significant infectious episodes with the rate of immune reconstitution in both patient groups.
Patients and methods

Patients
After informed consent, eight patients with rapidly progressive secondary MS (median age, 41 (range years; three were male) and 39 patients with hematological malignancies (median age, 51 (range 20-64) years; 21 were male) were included in the study. The difference in age between both patient groups was not significantly different. The MS patients had not received any prior cytoreductive therapy. Approximately 6-8 weeks before conditioning and stem-cell reinfusion, autologous bone marrow cells were harvested under general anesthesia from these patients. After CD34 positive selection, the CD34 positive cell fraction of the graft was cryopreserved in liquid nitrogen until further use. The conditioning regimen consisted of horse antithymocyte globulin (ATG; Me´rieux (Marcy-l'Etoile, France)) at a dose of 15 mg/kg intravenously (i.v.) from days À7 to À3. On days À4 and À3, cyclophosphamide (Cy; 60 mg/kg i.v.) was given combined with mesnum (15 mg/kg, 4 Â daily). Total body irradiation (TBI) was given in two fractions of 5 Gy each at days -2 and -1. On day 0, the autografts were thawed and reinfused. The diagnostic indications for autologous SCT of the HM patients were non-Hodgkin's lymphoma (n ¼ 21), multiple myeloma (n ¼ 11), acute lymphoblastic leukemia (n ¼ 3), acute myelogenous leukemia (n ¼ 3) and Hodgkin's disease (n ¼ 1). These patients had been pretreated with chemotherapy for remission induction and maintenance before myeloablative conditioning and SCT. Their peripheral blood stem cells were harvested after stimulation with granulocyte colony-stimulating factor (G-CSF, 5 mg/kg s.c. twice daily), and cryopreserved without further modification. Conditioning regimens consisted of procarbazine, etoposide, cytarabine and Cy (n ¼ 21); Cy and TBI (n ¼ 12); Cy and procarbazine (n ¼ 3); procarbazine and TBI (n ¼ 2); and Cy, procarbazine and etoposide (n ¼ 1). Following these conditioning regimens, the autografts were thawed and reinfused.
Infectious episodes
The occurrence of infections was evaluated during the first year after SCT. Clinically significant infections were defined as grade X2 according to the NCI common toxicity criteria. We analyzed infections during the first 100 days post SCT separately from those occurring after day 100, as we considered the first group of infections to be related to the direct effects of cytoreductive therapy such as mucosal toxicity and neutropenia. Infections were considered as 'proven' in case of clinical symptoms and microbiological and/or pathological proof. Alternatively, 'clinical' infections were defined as those with clinical symptoms, but without microbiological or pathological proof. Dermal herpes zoster infections were considered as 'proven' irrespective of the outcome of viral cultures. Infections with a protracted course were each scored as a single infectious event. Infections occurring after progression of MS or relapse of HM were excluded from this analysis.
Study design for immunological monitoring T-cell reconstitution studies, as detailed below, were performed before SCT, that is, immediately before conditioning, and at 2, 3, 6, 9 and 12 months post SCT. In three HM patients these studies were discontinued prematurely because of relapse of disease. In addition, neutrophil counts were assessed three times per week during hospitalization, and at larger intervals thereafter, in order to determine the time to neutrophil recovery (i.e., 0.5 Â 10 9 cells/l). For the T-cell reconstitution studies, reference ranges (defined by 5th and 95th percentiles) were determined in 160 healthy volunteer donors. The number of viable T-cells in the grafts (per kg body weight of the recipient) administered to the MS and HM patients was assessed by flow cytometry 17 and were compared to those in a control group of 19 allogeneic grafts obtained from healthy sibling donors.
Enumeration of lymphocyte subsets Blood samples (3 ml each) were anticoagulated with ethylene diamine tetra-acid (EDTA). Absolute lymphocyte counts were assessed using a 3-color stain-lyse-no wash single platform method. 18 A volume of 100 ml blood was pipetted in duplicate in TRUCOUNT tubes ( ). 20, 21 These six stainings were performed using a lyse-stain-wash assay. 22 Here, Falcon 2052 tubes not containing counting beads were used; following erythrocyte lysis using 2 ml FACS Lysing Solution, the cells were spun down, the supernatant removed by pipetting and the cell pellet resuspended in 250 ml phosphate-buffered saline (PBS) and kept in the dark for 2 h maximum until flow cytometric data acquisition.
All mAb used were purchased from BD Biosciences with the exception of CD45 mAb conjugated to PE-Cy5, TCRab/PE-Cy5 and CD4/PE-Cy5 which were purchased from Beckman Coulter (Miami, FL, USA); CD45RO/ FITC and CD8/PE were purchased from Dako (Glostrup, Denmark). Absolute numbers of lymphocyte subsets were calculated by multiplying the absolute lymphocyte count (tube 1) by the percentages of each subset (expressed as proportion of lymphocytes). For the absolute counts of lymphocytes and CD3 þ T-cells, the mean result of duplicate assessments (tube 1) were used.
In vitro induction of cytokine responses For this assay, 3 ml blood anti-coagulated with Na-heparin was drawn on the same time points as outlined above. One milliliter of blood was incubated for 4 h at 371C in a 50-ml tube with 25 ng/ml phorbol-12-myristate 13-acetate (PMA; Sigma, St Louis, MO, USA), 1 mg/ml ionomycin (Calbiochem, La Jolla, CA, USA) in RPMI-1640 medium (Gibco, Grand Island, NY, USA) in a final volume of 2 ml. To this mixture, 10 mg/ml brefeldin A (Epicentre Technologies, Madison, WI, USA) had been added from the start to inhibit the secretion of the produced cytokines. As negative control, a blood sample that had not been stimulated with PMA and ionomycin was included in each assay. Thereafter, 4 ml PBS containing 1% bovine serum albumin (PBS-BSA) was added, the cells spun down and the supernatant removed by pipetting. Erythrocytes were then lysed by adding 20 ml FACS Lysing Solution for 10 min at room temperature. Following centrifugation, the supernatant was removed and the leukocytes resuspended and permeabilized using 3 ml FACS Permeabilizing Solution (BD Biosciences) for 10 min at room temperature. The cells were then spun down, the supernatant removed and the cell pellet stained with a mixture of anti-TCRab PE-Cy5 þ CD8 FITC mAb. Following 30 min incubation at RT in the dark, the cells were washed once using PBS-BSA, resuspended in 300 ml PBS-BSA and aliquoted over six Falcon 2052 tubes for labeling with anti-IFNg PE, anti-IL2 PE, anti-TNFa PE, anti-IL4 PE, anti-IL13 PE and mouse IgG 1 PE (isotype control) mAb (all from BD Biosciences), respectively. Incubation with mAb was again for 30 min at RT, followed by washing and resuspending in 250 ml PBS until flow cytometry within 2 h. Ungated list mode data containing a minimum of 5000 TCRab þ lymphocytes were acquired from each tube.
For data analysis, the induction of cytokine responses was analyzed within the TCRab þ , CD8 bright lymphocytes (representing the CD8 þ T-cells) and the TCRab þ , CD8
À lymphocytes (representing the CD4 þ T-cells). This procedure, rather than identifying CD4 þ T-cells directly using a CD4 mAb, was followed because stimulation with PMA strongly downregulates CD4 expression. 23, 24 During data analysis, a threshold was set for each cell sample on the corresponding isotype control staining to distinguish between positive and negative fluorescence signals, and the proportions of cytokine-positive cells within the TCRab þ , CD8 À and TCRab þ , CD8 þ T-cell subsets were determined. Finally, any background signal in the corresponding unstimulated controls (i.e., the corresponding blood samples that had not been activated) was subtracted from that of the stimulated samples.
Statistical analyses
Patients experiencing a relapse of their original disease following SCT were censored at the time of relapse. Wilcoxon's rank sum test was used to compare, per parameter, data from two patient groups. To compare the incidence of infections between the MS and HM patient groups, the incidence rates were calculated and compared as described elsewhere. 25 All P-values were two-sided, and P-values p0.05 were considered statistically significant unless as detailed below. For the comparison of data from MS or HM patients with those of healthy controls, or the comparison of data from MS with those of HM patients for each time point relative to SCT (Figures 2-6 ), Wilcoxon's rank sum test was used with adjustment for multiple testing, that is, 25 parameters ((15 T-cell markers þ five cytokine assessments on CD4 þ T cells) þ (five cytokine assessments on CD8 þ T cells)) Â six time points yields a factor of 150, so that only P-values less than 0.05C150 ¼ 0.0003 were considered significant. The matched-pair t-test was used to compare, per patient and immune parameter, of post transplant data with the corresponding pre-transplant data, again with adjustment for multiple testing (see legends to Figures 2-6).
Results
T-cell content of the stem cell grafts
The CD34 þ cell-selected autografts of the MS patients contained three to four logs less T-cells than the non-T-celldepleted autografts of the HM patients (median o0.01 Â 10 6 versus 109 Â 10 6 T-cells per kg body weight of the recipient; P ¼ 0.0001; Figure 1) . However, the non-depleted autografts of the HM patients contained still fewer T-cells than the non-depleted grafts from allogeneic, healthy stem cell donors (median 109 Â 10 6 versus 261 Â 10 6 T-cells per kg body weight of the recipient; P ¼ 0.01), reflecting the T-lymphopenia of the HM patients at the time of hematopoietic stem cell mobilization.
Kinetics of neutrophil recovery
The time for neutrophils to reach the 0.5 Â 10 9 /l threshold was significantly longer in the MS patients (i.e., median 27 (range 12-38) days) than in the HM patients (i.e., median 15 (range 11-73) days; Po0.01).
Recovery of circulating T-cell subsets
Before transplant, the median group values of the absolute counts of the T-cells as defined by their receptor type (i.e., TCRab and TCRgd), as well as the CD4 þ and CD8 þ Tcell subsets of the MS patients were all within their normal ranges ( Figure 2 ). This was also the case with both CD4 Only the CD8 þ T-cell subset showed a rapid recovery after SCT in both MS and HM patients. Its median group value had attained the normal range by 2 months (Figure 2 , lower right panel). In contrast, the reappearance of CD4 þ T-cells was remarkably slow in both patient groups and their median values for both patient groups had not yet reached the lower limit of the normal range at 12 months. Of note, the rate of CD4 þ T-cell reconstitution during the first 6 months tended to be slower in the MS patients than in the HM patients (Figure 2, lower left panel) . Similarly, the reconstitution of the TCRab þ and TCRgd þ T-cells in the MS patients lagged slightly behind that in the HM patients ( Figure 2 , upper panels). Months after autologous SCT Absolute cell count The delayed reconstitution of CD4 þ T-cells was mainly due to a slow recovery of 'naı¨ve' CD4 þ CD45RO À T-cells in both patient groups (Figure 3, left panel) . In contrast, the 'primed' CD4 þ CD45RO þ T-cells recovered at a faster rate, that is, their median group value reached the lower limit of the normal range at 2 months in the HM patients, and at 12 months in the MS patients ( Figure 3, right panel) . The median group values of the 'effector memory' CD4 
þ , 62L þ ) remained below the lower limits of their normal ranges during the 12 months of follow-up in both patient groups (Figure 4 , left panels).
Expression of HLA-DR and CD95 markers
Before SCT, HLA-DR expression by the major TCRab þ T-cell subset was normal in MS patients but increased in HM patients. After SCT, T-cell activation as indicated by À T-cells: 3 months. Post transplant, the MS patient data did not differ significantly from the corresponding pre-transplant data at any of the studied time points. The HM patient data differed significantly from controls as follows: increased HLA-DR expression by the TCRab þ T-cells was apparent in both patient groups; this expression was highest at 2 months and returned to its normal range at 12 months post SCT ( Figure 5, left panel) .
The expression of the apoptosis receptor CD95 by CD4 þ and CD8 þ T-cells showed a large variation in normal subjects ( Figure 5 , middle and right panels, respectively). Before SCT, the HM patients had significantly higher levels of CD95 expression by their CD4 þ and CD8 þ T-cells than the MS patients. After SCT, the CD4 þ T-cells of the MS patients showed a strong increase of their CD95 expression by their CD4
þ T-cells with median group values exceeding the normal ranges between 3 and 9 months. The expression of CD95 by the CD4 þ T-cells of the HM patients remained strongly elevated during the entire period of follow-up ( Figure 5 , middle panel). After SCT, the CD95 expression by the CD8 þ T-cells of the MS patients increased to similar levels as seen on those of HM patients. However, the median group values of CD95 expression by the CD8 þ T-cells in both MS and HM groups remained within the normal range, although a large variation between patients was observed ( Figure 5, right panel) .
Cytokine responses by CD4
þ and CD8 þ T-lymphocytes The intracellular expression of IFN-g ( Figure 6 , left panels) and TNF-a (data not shown) by CD8 À (ECD4 þ ) T-cells after stimulation with PMA and ionomycin showed a considerable variation between apparently healthy donors. This variation was smaller for IL-2 ( Figure 6 , right panels), while hardly any induction of IL-4 and IL-13 expression was observed (data not shown).
Before SCT, the group median values of all cytokine responses of the CD4 þ and CD8 þ T-cells of the MS patients were within the normal range. In contrast, all cytokine responses except IL-2 of both CD4 þ and CD8 þ T-cells of the HM patients were increased as compared to the healthy controls, indicating their activated state ( Figure  6 and data not shown).
Following SCT, the group median values of the IFN-g and TNF-a responses of the CD8 þ T-cells of the MS patients fluctuated around the upper limit of the normal range, while the corresponding responses of the CD4 þ T-cells were not increased ( Figure 6 , left panels, and data not shown). In contrast, the IL-2 responses of the CD4 þ and CD8
þ T-cells between 2 and 6 months were relatively low ( Figure 6 , right panels), while hardly any induction of IL-4 and IL-13 was seen (data not shown). The cytokine responses of the CD4 þ and CD8 þ T-cells of the HM patients followed, by and large, similar patterns post SCT as described for the MS patients, except for higher IFN-g but not TNF-a responses by the CD4 þ T-cells ( Figure 6 , upper left panel, and data not shown).
Infectious complications post SCT
During the first 100 days post SCT no statistically significant differences in the occurrence of infectious complications between both patient groups were observed (Table 2) . Infectious complications between 3 and 12 months post SCT were rare among the MS patients and more frequent among the HM patients, but this difference did not reach significance.
Discussion
We set out to compare the rate of T-cell reconstitution and the occurrence of infectious complications after autologous SCT in two settings: one with extensive ex vivo and in vivo T-cell depletion administered to patients with MS, and one of unmodified autografts given to patients as consolidation therapy for HM. We expected that the rate of T-cell recovery in the intensively T-depleted MS patients would be delayed and that, therefore, these patients would be predisposed for significant infectious complications. Reportedly, both viral and bacterial infections reportedly occur more frequently after autologous SCT that had been enriched for CD34 þ hematopoietic stem cells (and thus had been depleted of T-cells) than after unmodified autografting. 26 However, the rates of infections in our MS and HM patient cohorts were not significantly different, neither during the first 100 days nor between 100 and 365 days post SCT. During the latter period, we observed only two clinically significant infectious episodes in eight MS patients.
Also unexpected was the similar kinetics of T-cell reconstitution from 3 to 12 months post SCT in the MS and HM groups, both in terms of absolute counts of circulating T-cell subsets as in functional terms (i.e., expression of activation markers and intracellular IFN-g, IL-2 and TNF-a following universal lymphocyte stimulation). The reconstitution of the CD4 þ T-cells, in particular that of the 'primed' CD4 þ , 45R0 þ subset, tended to be delayed in the MS patients, but this difference with the HM patients did not reach significance. A limitation of our study design was that T-cell monitoring was only started by 2 months post SCT, and that any differences between the two groups before that time have not been recorded. Several factors would have contributed to an initially slower rate of (T-cell) engraftment in the MS patients: (i) the 3-4 log T-cell depletion of their grafts; (ii) the depletion of residual (and any incoming) T-cells by ATG treatment; and (iii) the source of stem cells (bone marrow derived versus peripheral blood derived in the HM patients). 27 We consider it unlikely that the somewhat younger age of the MS patients would have offset their disadvantage with respect to T-cell reconstitution rate as compared to the HM patients, 14, 28 as the ages of both groups were not significantly different. However, both groups did differ with respect to the rate of neutrophil engraftment, which was delayed in the MS patients. Here, the source of the stem cells (bone marrow) and the T-cell depletion of the autografts may have played a role.
Our immunophenotypic studies confirm and extend earlier observations on T-cell reconstitution after autologous SCT: (i) a very protracted recovery of CD4 þ Tcells, 9, 15, 29, 30 in particular that of the 'naive' CD4 þ , 45R0
þ T-cells, the 'central memory' cells expressing the CD62L and CD27 markers were the slowest to recover; 15, 16 (ii) a relatively slow recovery of TCR-gd þ T-cells; (iii) a rapid normalization of CD8 þ T-cell counts; 8, 15, [29] [30] [31] 33 (iv) initially, a strong upregulation of HLA-DR expression by TCRab þ T-cells, gradually declining to normal at 12 months; 12, 30 and (v) upregulation of the apoptosis marker CD95, in particular by the CD4 þ T-cells. 16, 34 With respect to cytokine responses, our observation that the capability of CD4 þ and CD8 þ T-cells to produce IFN-g, IL-2 and TNF-a had reached their normal ranges from 2 months post SCT onwards is consistent with that of others. 30 However, the post transplant levels of IFN-g and TNF-a production by the CD8 þ T-cells in our two patient groups were supranormal, which may fit with their activated state (see also below). Before conditioning and SCT, we observed important differences between the circulating T-cells in the MS and HM patients. While the MS patients had normal T-cell subset counts, normal levels of the activation markers HLA-DR and CD95 and normal cytokine responses by their CD4 þ and CD8 þ T-cells, the HM patients showed lymphopenia of all T-cell subsets, upregulated HLA-DR and CD95 expression and increased cytokine responses except for IL-2. Similar observations have been made in other studies of adult patients treated with high-dose chemotherapy [35] [36] [37] with, as a result, an impact on the phenotype of the T-cells in their autografts. 38 In this context it is important that the autografts of our HM patients contained significantly less T-cells than allografts obtained from otherwise healthy donors (Figure 1) . Following high-dose chemotherapy, the 'naive' CD4 þ and CD8
þ T-cells in the HM patients were especially slow to regenerate, 35, 36 while the main wave of regeneration from 'primed' CD4 þ T-cells was only temporary, declining between 9 and 12 months after chemotherapy. 35 The high levels of CD95 expression by post chemotherapy
CD4
þ T-cells explain their increased susceptibility to apoptosis following in vitro stimulation with mitogens, 34, 35 which may reflect a regulatory response to their increased level of activation. Of note, triggering of CD27 -expressed on 'central memory' CD4 þ , 45R0 þ T-cells -has been shown to sensitize these cells for CD95-induced apoptosis. 39 Therefore, we suggest that the progeny of the activated CD4
þ T-cells in the autografts of our HM patients are prone to apoptosis and, as a consequence, cannot achieve a swift and sustained T-cell regeneration post SCT. The net result would be a delayed CD4 þ T-cell regeneration similar to as observed in the MS patients after their ex vivo and in vivo T-cell depletion.
In conclusion, a remarkable finding in this autologous SCT study was that the CD4 þ T-cell recovery following chemotherapy and unmodified SCT was delayed to a similar rate as observed after chemoradiotherapy and extensive ex vivo and in vivo T-cell depletion. In this context it is interesting to recall the observations by Porrata and co-workers describing the beneficial effect of early lymphocyte recovery on the overall survival time after autologous SCT (reviewed in Porrata and Markovic 40 ). Although the mechanism of this effect is not certain, it is fair to speculate that lymphocytes in the grafts contribute to this effect. Extrapolation of our current results to those of Porrata et al. would imply that autograft collection should be timed when the patients are immunologically still normal, for example, have normal CD4
þ T-cell counts without an activated immunophenotype. Table 2 Infectious complications before and after day 100 post SCT 
